Skip to main content

Table 1 Baseline Demographics

From: Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry

Characteristic

N

Mean (SD)

Median

Range

Age, years

    

  All subjects

120

9.2 (3.8)

9.6

1.6, 16.9

  Boys

90

9.20 (4.09)

9.6

1.6, 16.9

  Girls

30

9.24 (2.98)

9.6

2.8, 14.2

HSDS

    

  All subjects

120

–2.6 (0.7)

–2.6

–4.5, –1.2

  Boys

90

–2.6 (0.74)

–2.44

–4.5, –1.2

  Girls

30

–2.9 (0.67)

–2.88

–4.1, –1.7

Target HSDS

99

–0.3 (0.9)

–0.2

–3.8, 2.0

IGF-1 SDS

73

–3.0 (1.5)

–2.8

–8.2, 0.6

Bone age, years

93

7.7 (3.8)

7.8

0.5, 15.5

Maximal GH, ng/ml

34

11.7 (8.4)

10.0

0.8, 39.3

BMI

120

16.4 (2.0)

16.1

13.2, 26.9

Weight, kg

120

23.9 (9.4)

22.8

8.3, 51.6

  1. BMI, body mass index; GH, growth hormone; HSDS, height standard deviation score; SD, standard deviation.